Antibiotics-Basel

Scope & Guideline

Advancing antibiotic research for a healthier tomorrow.

Introduction

Welcome to your portal for understanding Antibiotics-Basel, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2079-6382
PublisherMDPI
Support Open AccessYes
CountrySwitzerland
TypeJournal
Converge2010, from 2012 to 2024
AbbreviationANTIBIOTICS-BASEL / Antibiotics-Basel
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND

Aims and Scopes

The journal 'Antibiotics-Basel' focuses on the multifaceted field of antibiotic research, encompassing various aspects of antimicrobial resistance, novel therapies, and the implications of antibiotic use across different settings. The journal aims to provide a comprehensive platform for researchers to share innovative findings that contribute to understanding and combating antibiotic resistance, improving patient outcomes, and enhancing public health.
  1. Antimicrobial Resistance Mechanisms:
    Research on the genetic, biochemical, and environmental factors contributing to the emergence and spread of antimicrobial resistance genes in various microbial populations.
  2. Novel Antimicrobial Agents:
    Development and evaluation of new antibiotics, including synthetic compounds, natural products, and their mechanisms of action against resistant pathogens.
  3. Antibiotic Stewardship Practices:
    Studies evaluating the effectiveness of antimicrobial stewardship programs in hospitals and community settings to optimize antibiotic use and reduce resistance.
  4. Clinical Outcomes and Pharmacokinetics:
    Research on the pharmacokinetics and pharmacodynamics of antibiotics, including dosing strategies and their impact on clinical outcomes in various populations.
  5. Environmental Impact of Antibiotics:
    Exploration of antibiotic residues in the environment and their role in selecting for resistant strains, including studies on wastewater treatment and agricultural runoff.
  6. One Health Approach to Antibiotic Use:
    Interdisciplinary research that addresses antibiotic resistance across human, animal, and environmental health sectors, emphasizing the interconnectedness of these fields.
The journal 'Antibiotics-Basel' is witnessing significant growth in specific research areas, reflecting current challenges and advancements in the field of antimicrobial resistance and therapy. The following emerging themes highlight the latest trends and priorities in antibiotic research.
  1. Phage Therapy and Alternative Treatments:
    An increasing number of studies are exploring bacteriophage therapy as a viable alternative to traditional antibiotics, especially for multi-drug-resistant infections.
  2. Environmental Antibiotic Resistance Studies:
    There is a growing focus on understanding the environmental factors contributing to the spread of antibiotic resistance, including studies on wastewater treatment and agricultural practices.
  3. Machine Learning and AI in Antibiotic Research:
    The integration of artificial intelligence and machine learning techniques to predict antibiotic resistance patterns and optimize treatment protocols is emerging as a significant trend.
  4. Antimicrobial Peptides (AMPs):
    Research into the development and application of antimicrobial peptides as novel therapeutic agents against resistant pathogens is gaining momentum.
  5. Impact of Antibiotic Stewardship on Clinical Outcomes:
    There is an increasing emphasis on evaluating the real-world impact of antimicrobial stewardship programs on patient outcomes and healthcare costs.
  6. Resistance Mechanisms in Emerging Pathogens:
    A trend towards investigating resistance mechanisms in new and emerging pathogens, particularly in the context of zoonotic diseases and public health implications.

Declining or Waning

While 'Antibiotics-Basel' has a broad and evolving scope, certain themes appear to be declining in prominence based on recent publication trends. This section highlights these waning areas of focus, which may reflect shifts in research priorities or emerging challenges in the field.
  1. Traditional Antibiotic Usage Studies:
    There has been a noticeable decrease in studies solely focused on traditional antibiotic usage patterns without integrating newer approaches or technologies.
  2. Single-Agent Antibiotic Efficacy Studies:
    Research focusing exclusively on the efficacy of single antibiotics is waning as there is a growing emphasis on combination therapies and multi-drug approaches to combat resistance.
  3. Basic Research on Antibiotic Mechanisms:
    While still relevant, the focus on purely mechanistic studies of antibiotics is declining in favor of translational research that bridges laboratory findings with clinical applications.
  4. Antibiotic Resistance in Non-Clinical Settings:
    There is a noticeable decrease in studies addressing antibiotic resistance in non-clinical environments, such as community settings outside hospitals, as the focus shifts towards clinical implications and hospital-acquired infections.

Similar Journals

Pneumonia

Fostering Global Collaboration in Respiratory Health
Publisher: BMCISSN: 2200-6133Frequency: 1 issue/year

Pneumonia is an esteemed open-access journal published by BMC, focusing on a comprehensive range of topics related to pneumonia and respiratory diseases. Since its inception in 2012, the journal has been dedicated to disseminating high-quality research that advances scientific understanding and clinical practices in the field. With an ISSN of 2200-6133, this journal provides researchers, healthcare professionals, and students with immediate access to groundbreaking studies, systematic reviews, and clinical guidelines that address the global challenges posed by pneumonia. By facilitating the open exchange of knowledge, Pneumonia significantly contributes to the enhancement of patient care and the development of effective treatment strategies. Situated in the heart of London, Pneumonia harnesses the strengths of the BMC platform to maintain high academic standards and reach a diverse international audience.

JOURNAL OF MICROBIOLOGY

Connecting global minds in the realm of microbiology.
Publisher: MICROBIOLOGICAL SOCIETY KOREAISSN: 1225-8873Frequency: 12 issues/year

JOURNAL OF MICROBIOLOGY, published by the Microbiological Society Korea, is a prestigious peer-reviewed journal dedicated to the advancement of knowledge in the fields of microbiology, applied microbiology, and biotechnology. Established in 1996, this journal serves as a vital platform for researchers and professionals from around the globe to disseminate their findings and engage in multidisciplinary discussions pertaining to microbial sciences. With an H-index that reflects its impact, the journal holds a commendable Q2 ranking in key categories including Applied Microbiology and Biotechnology, as well as Medicine (Miscellaneous), which underscores its significance in the academic community. Despite being a subscription-based journal, the JOURNAL OF MICROBIOLOGY aims to contribute to the understanding of microbial processes and their applications, facilitating advancements that are essential in health, industry, and environmental sciences. Researchers, students, and practitioners are encouraged to explore this rich resource for the latest research and trends in microbiology.

Journal of the Pediatric Infectious Diseases Society

Pioneering insights for a healthier tomorrow.
Publisher: OXFORD UNIV PRESSISSN: 2048-7193Frequency: 4 issues/year

Journal of the Pediatric Infectious Diseases Society, published by Oxford University Press, stands as a pivotal platform for advancing knowledge in the realm of pediatric infectious diseases. With an ISSN of 2048-7193 and an E-ISSN of 2048-7207, this esteemed journal has garnered significant recognition in the academic community, achieving influential rankings such as Q1 in Pediatrics, Perinatology and Child Health and Q2 in Infectious Diseases. With converged years from 2012 to 2024, it aims to publish cutting-edge research, reviews, and clinical practices that address the challenges and innovations in the field. The journal's strong performance, reflected in its Scopus ranks (33rd percentile in Pediatrics and 97th in Infectious Diseases), underscores its impact on the global healthcare landscape. As a non-open access journal, it provides exclusive content essential for researchers, medical professionals, and students dedicated to enhancing pediatric healthcare outcomes.

Microbial Drug Resistance

Illuminating the Path to Effective Antimicrobial Strategies
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

FEMS MICROBIOLOGY LETTERS

Advancing the Frontiers of Microbial Knowledge
Publisher: OXFORD UNIV PRESSISSN: 0378-1097Frequency: 1 issue/year

FEMS Microbiology Letters, published by Oxford University Press, is a prestigious international journal dedicated to advancing the understanding of microbiology through concise and impactful research articles. With an ISSN of 0378-1097 and E-ISSN 1574-6968, this journal encompasses a wide range of topics within the fields of genetics, microbiology, and molecular biology, achieving a notable Q3 quartile ranking in these categories as of 2023. As an essential platform for researchers, professionals, and students, FEMS Microbiology Letters invites submissions that contribute valuable insights into microbial behaviors, genetic mechanisms, and innovative methodologies pivotal in the study of microbiology. Although it is not an open-access publication, the journal's rigorous editorial standards ensure high-quality content that is relevant and significant to its audience, furthering scholarly dialogue and collaboration in the vibrant field of microbiological research.

HELICOBACTER

Advancing Gastroenterology Through Innovative Research
Publisher: WILEYISSN: 1083-4389Frequency: 6 issues/year

HELICOBACTER is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of gastroenterology and infectious diseases. With an impressive impact factor that places it in the Q1 quartile across three critical categories—gastroenterology, infectious diseases, and miscellaneous medicine—it signifies the journal's crucial role in disseminating high-quality research and fostering academic dialogue. Commencing publication in 1996, HELICOBACTER has established itself as a pivotal platform for innovative studies, case reports, and reviews, focusing on Helicobacter species and their clinical implications, thus attracting a global audience of researchers, healthcare professionals, and students eager to stay at the forefront of the field. Despite not being an open-access journal, its strong reputation is reinforced by its Scopus ranks, where it stands impressively at #19 out of 167 in gastroenterology, placing it in the 88th percentile among its peers. As a vital resource for those engaged in gastrointestinal and infectious research, HELICOBACTER continues to contribute significantly to the understanding and management of Helicobacter-related conditions.

Lancet Microbe

Bridging Gaps in Infectious Disease Research
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

The Lancet Microbe is a leading peer-reviewed journal published by ELSEVIER, focused on advancing research in the fields of infectious diseases, microbiology, and virology. Since its inception in 2020, this open-access journal has rapidly achieved a prestigious reputation, evidenced by its impressive rankings in the Scopus Ranks, where it holds positions within the top 10 in multiple categories and boasts high percentiles, reflecting the impact and relevance of its published works. With a quarterly publication schedule, the Lancet Microbe aims to disseminate critical findings and foster innovation within the scientific community, providing a platform for researchers and professionals to share their significant contributions. The journal is committed to facilitating knowledge exchange and accessibility, making it an essential resource for academicians and practitioners dedicated to addressing global health challenges.

Journal Of Bone And Joint Infection

Advancing the frontier of bone and joint infection research.
Publisher: COPERNICUS GESELLSCHAFT MBHISSN: Frequency: 1 issue/year

Journal of Bone and Joint Infection, published by COPERNICUS GESELLSCHAFT MBH, is a pioneering open-access journal dedicated to the multidisciplinary field of bone and joint infections. Since its inception in 2016, it has served as a vital platform for researchers and practitioners to share cutting-edge findings, clinical practices, and innovative research methodologies from around the globe. Based in Germany, this journal has quickly established itself with a significant impact, currently holding a Q3 placement in Infectious Diseases and Q2 in both Orthopedics & Sports Medicine and Surgery, alongside commendable Scopus rankings. With the aim of advancing knowledge and fostering collaboration in the treatment and understanding of osteoarticular infections, the journal invites submissions that contribute to the scientific community's quest for effective management strategies and improved patient outcomes. The open-access format ensures that groundbreaking research is readily accessible, promoting wider dissemination and visibility within the community. As the Journal of Bone and Joint Infection continues through its converged years (2016-2024), it remains committed to supporting ongoing education and innovation in this critical area of medical research.

JOURNAL OF CHEMOTHERAPY

Empowering Innovations in Oncology and Pharmacology
Publisher: TAYLOR & FRANCIS LTDISSN: 1120-009XFrequency: 6 issues/year

Journal of Chemotherapy is a distinguished peer-reviewed academic journal published by Taylor & Francis Ltd, focusing on the dynamic fields of infectious diseases, oncology, and pharmacology. With its ISSN 1120-009X and E-ISSN 1973-9478, this journal has been at the forefront of chemotherapy research since its inception in 1989 and continues to play a vital role in advancing medical science through rigorous studies and reviews. It currently holds a respectable position in various Scopus categories, ranked Q3 in several important disciplines, reflecting its commitment to providing quality research. Although it operates under a subscription model, Journal of Chemotherapy remains a crucial resource for practitioners and academics alike, facilitating knowledge exchange and innovation in the treatment of diseases through chemotherapy. With access to the latest findings and therapeutic advancements, this journal is a must-read for researchers, medical professionals, and students seeking to enhance their understanding of emerging trends in chemotherapy.

Surgical Infections

Advancing knowledge in surgical infection management.
Publisher: MARY ANN LIEBERT, INCISSN: 1096-2964Frequency: 10 issues/year

Surgical Infections, published by MARY ANN LIEBERT, INC, is an esteemed journal dedicated to advancing the understanding and management of infections associated with surgical procedures. With an ISSN of 1096-2964 and an E-ISSN of 1557-8674, this journal has emerged as a vital resource within the fields of Infectious Diseases, Surgery, and Microbiology. Over the years, it has established a notable presence, achieving a 2023 Q2 ranking in Infectious Diseases and Surgery, as well as a Q3 ranking in Microbiology. The journal holds an impressive position at 74th percentile in Surgery according to Scopus, making it a reliable platform for disseminating current research and clinical practices. Surgical Infections aims to provide an interdisciplinary forum for both seasoned professionals and academics, encouraging the exploration of novel therapeutic approaches, prevention strategies, and case studies that address the complexities of surgical-related infections. As the field continues to evolve, this journal remains committed to fostering innovative research that enhances clinical outcomes and patient safety.